Monika E. Hegi

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations

Medicine, Oncology, Radiation Oncology +17

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text

Medicine, Molecular Biology, Oncology +17

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · JAMA · 2017 · 2.6K citations · Full text

Medicine, Neurosurgery, Oncology +16

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Annika Malmström, Bjørn Henning Grønberg, Christine Marosi et al. · The Lancet Oncology · 2012 · 1.3K citations

Medicine, Oncology, Radiation Oncology +12

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · JAMA · 2015 · 1.2K citations · Full text

Medicine, Oncology, Radiation Oncology +15